Literature DB >> 1703047

Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937.

N Keicho1, S Sawada, K Kitamura, H Yotsumoto, F Takaku.   

Abstract

A recently discovered immunosuppressive agent, FK506, has been shown to be effective primarily as an inhibitor of T cell responses in vitro, but little is known about its effects on accessory cell function. This study was undertaken to determine the effect of FK506 on interleukin 1 (IL-1) production by macrophages, by using a sensitive and specific enzyme-linked immunosorbent assay. FK506 partially suppressed IL-1 alpha release, from macrophage-like U937 cells stimulated with phorbol myristate acetate and from human monocytes and alveolar macrophages activated with lipopolysaccharide, in a dose-dependent manner. Moreover, it was indicated that FK506 suppressed not only IL-1 release but also IL-1 synthesis itself, by measurement of cell-associated IL-1 alpha of U937 cells. The optimal concentrations of FK506 for suppressing IL-1 alpha did not affect cell viability or proliferation, and were 10- to 100-fold lower than those of cyclosporin A. It is concluded that FK506 affects macrophage physiology, suppressing IL-1 alpha production significantly. Thus, FK506 has the potency to act on non-T cells and the effect on macrophages may play an additional role in preventing graft rejection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703047     DOI: 10.1016/0008-8749(91)90028-a

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.

Authors:  Melissa K McCoy; Terina N Martinez; Kelly A Ruhn; David E Szymkowski; Christine G Smith; Barry R Botterman; Keith E Tansey; Malú G Tansey
Journal:  J Neurosci       Date:  2006-09-13       Impact factor: 6.167

2.  Porphyromonas gingivalis lipopolysaccharide-stimulated bone resorption via CD14 is inhibited by broad-spectrum antibiotics.

Authors:  Y Miyata; H Takeda; S Kitano; S Hanazawa
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

3.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

Review 4.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood.

Authors:  M J Schultz; P Speelman; S Zaat; S J van Deventer; T van der Poll
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

6.  Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells.

Authors:  J E Garcia; M R de Cabo; F M Rodríguez; J P Losada; A J López; J L Arellano
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

7.  Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level.

Authors:  J E García; A M López; M R de Cabo; F M Rodríguez; J P Losada; R G Sarmiento; A J López; J L Arellano
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

8.  Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis.

Authors:  Weilan Huang; Shiqi Ling; Xiuhua Jia; Binwu Lin; Xi Huang; Jing Zhong; Weihua Li; Xiaolei Lin; Yifang Sun; Jin Yuan
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.

Authors:  Xiao Wu; Don Hayes; Joseph B Zwischenberger; Robert J Kuhn; Heidi M Mansour
Journal:  Drug Des Devel Ther       Date:  2013-02-04       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.